3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Lung Neoplasms
5
Small Cell Lung Carcinoma
4
Mesothelioma
3
Neoplasms
2
Neoplasm Metastasis
2
Mesothelioma, Malignant
2
Carcinoma, Non-Small-Cell Lung
2
Uveal Melanoma
1
Urologic Neoplasms
1
Stomach Neoplasms
1
SCLC,Extensive Stage
1
Recurrence
1
Pancreatic Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Neuroendocrine
1
Carcinoma
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
24
Magnetic Resonance Spectroscopy
10
Carboplatin
8
Nivolumab
7
Docetaxel
7
Paclitaxel
6
Gemcitabine
6
Trastuzumab
5
Taxes
5
Injections
5
Fluorouracil
5
Fluorodeoxyglucose F18
5
Drug Therapy
5
Cyclophosphamide
5
Cisplatin
5
fludarabine
4
X-Rays
4
Specimen Handling
4
Radiotherapy
4
Psychiatric Rehabilitation
4
Polymerase Chain Reaction
4
Leucovorin
4
durvalumab
3
atezolizumab
3
Surveys and Questionnaires
3
Standard of Care
3
Irinotecan
3
Immunohistochemistry
3
Gene Expression Profiling
3
Early Intervention, Educational
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
niraparib
×
Thoracic
×
Clear all
NCT05169437
2025-10-29
PAVO
Tempus AI
Phase 2
Terminated
22 enrolled
17 charts